| Name | Title | Contact Details |
|---|---|---|
Rachel Lenington |
Chief Technology Officer and Head of Product Development Strategy | Profile |
Rachel Lenington |
Chief Operating Officer | Profile |
The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.
Starting a century ago, CSL Behring made a promise to save lives and protect the health of people stricken with a range of serious and chronic medical conditions. Today that same promise has never been stronger. With operations in more than 30 nations and over 12,000 employees worldwide, we develop and deliver biotherapies to prevent and treat people with life-threatening medical conditions. Our broad-range of therapies include those to treat disorders such as hemophilia and primary immune deficiencies. We collaborate with patient and biomedical communities to improve access to therapies, advance scientific knowledge, and support future medical research. Our world-class commercial operation, combined with a large and focused R&D team and operational excellence, enable us to accurately identify, successfully develop, and dependably deliver innovations that patients and providers want. For a century, CSL Behring has earned a reputation as a passionate yet responsible organization, driven to care for patients and deliver on its commitments.
We never stop striving for a better future. A true passion for improving patient lives. Medical education - The surgeon is never alone.
AliveDx is a leading diagnostics company that is revolutionizing the field. They provide high quality blood bank reagents called Alba, as well as MosaiQ®, which is the worlds first automated testing platform. Their innovative solutions are designed to...
One of the leading health care sources in the nation. We offer certified, medical grade supplies worldwide. info@crowdhealth.org